texas oncology more breakthroughs. more victories

Tyler Research and Clinical Trials

Texas Oncology-Tyler participates in a wide range of clinical trials and groundbreaking cancer research that is paving the way for new breakthroughs in cancer care. If you are a Texas Oncology patient in Tyler, you may be able to take part in these innovative clinical trials.

Texas Oncology-Tyler (Expand)

Biliary Cancer

Ph1b/2 BEMA FGFR2b ST Basket Trial

A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104) Read Moreabout Ph1b/2 BEMA FGFR2b ST Basket Trial

Phase: I/II

Ph2/3 CTX-009 + Paclitaxel vs. Paclitaxel in mBiliary Tract

A Phase 2/3 Randomized Controlled Study of CTX-009 in Combination with Paclitaxel versus Paclitaxel Alone in Adult Patients with Unresectable Advanced Metastatic or Recurrent Biliary Tract Cancers who have received One Prior Systemic Chemotherapy Regimen (CTX-009-002) Read Moreabout Ph2/3 CTX-009 + Paclitaxel vs. Paclitaxel in mBiliary Tract

Phase: II/III

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Bladder Cancer

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Blood Cancer

Ph2 Sub Mosunetuzumab B-cell malig

AN OPEN-LABEL MULTICENTER PHASE II TRIAL EVALUATING THE SAFETY EFFICACY AND PHARMACOKINETICS OF SUBCUTANEOUS MOSUNETUZUMAB MONOTHERAPY IN PATIENTS WITH SELECT B-CELL MALIGNANCIES (ML43389) Read Moreabout Ph2 Sub Mosunetuzumab B-cell malig

Phase: II

Breast Cancer

Ph1b/2 BEMA FGFR2b ST Basket Trial

A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104) Read Moreabout Ph1b/2 BEMA FGFR2b ST Basket Trial

Phase: I/II

Ph3 Dato Deru +/- Dura tri- BC Lymph nodes (TROPION-Breast03)

A Phase 3 Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)(D926XC00001) Read Moreabout Ph3 Dato Deru +/- Dura tri- BC Lymph nodes (TROPION-Breast03)

Phase: III

Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1)

A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301) Read Moreabout Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1)

Phase: III

Ph3 Study of DB1303 in HER2 with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02)

A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002) Read Moreabout Ph3 Study of DB1303 in HER2 with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02)

Phase: III

Ph3 HR+/HER2- BC (OVELIA)

A Phase 3 Single Arm Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer (TOL2506A; OVELIA) Read Moreabout Ph3 HR+/HER2- BC (OVELIA)

Phase: III

Ph3 HER2/neu BC (FLAMINGO-01)

A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01) Read Moreabout Ph3 HER2/neu BC (FLAMINGO-01)

Phase: III

Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001) Read Moreabout Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

Phase: III

Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4)

EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH) Read Moreabout Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4)

Phase: III

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

FLEX Registry: Evaluate New Gene Express

MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry) Read Moreabout FLEX Registry: Evaluate New Gene Express

Ph3 AZD9833 HR+/HER2- mBC -ctDNA (SERENA-6)

SERENA-6: A Phase III Double-blind Randomised Study to Assess Switching to AZD9833 (a Next Generation Oral SERD) + CDK4/6 Inhibitor vs Continuing Aromatase Inhibitor (Letrozole or Anastrozole) + CDK4/6 Inhibitor in HR+/HER2- MBC Patients with Detectable ESR1 Mutation Without Disease Progression During 1L Treatment with Aromatase Inhibitor + CDK4/6 Inhibitor Read Moreabout Ph3 AZD9833 HR+/HER2- mBC -ctDNA (SERENA-6)

Phase: III

Cervical Cancer

Ph1b/2 BEMA FGFR2b ST Basket Trial

A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104) Read Moreabout Ph1b/2 BEMA FGFR2b ST Basket Trial

Phase: I/II

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Colon Cancer

Ph1b-XL092 Immun Onco mST

A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002) Read Moreabout Ph1b-XL092 Immun Onco mST

Phase: I

Ph2 RO7198457 CRC ctDNA+ Post Resection

A multi-site open-label Phase II randomized controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection (BNT122-01) Read Moreabout Ph2 RO7198457 CRC ctDNA+ Post Resection

Phase: II/III

Ph2 Epidemi Colon Cancer

Epidemiological study to determine the prevalence of ctDNA positivity in participants with Stage II (high risk) or Stage III CRC after surgery with curative (R0) intent and subsequent adjuvant chemotherapy with monitoring of ctDNA during clinical follow-up (BNT000-001) Read Moreabout Ph2 Epidemi Colon Cancer

Phase: II/III

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Endometrial Cancer

Ph1b/2 BEMA FGFR2b ST Basket Trial

A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104) Read Moreabout Ph1b/2 BEMA FGFR2b ST Basket Trial

Phase: I/II

Ph3 Selin P53 Endo Carcinoma

A PHASE 3 RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY AFTER SYSTEMIC THERAPY FOR PATIENTS WITH P53 WILD-TYPE ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA (ENGOT-EN-20/GOG-3083/ XPORT-EC-042) Read Moreabout Ph3 Selin P53 Endo Carcinoma

Phase: III

INCMGA00012 Endo Cancer

An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (INCMGA 0012-204/ POD1UM-204) Read Moreabout INCMGA00012 Endo Cancer

Phase: II

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Esophageal Cancer

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Fallopian Tube Cancer

Ph1b/2 BEMA FGFR2b ST Basket Trial

A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104) Read Moreabout Ph1b/2 BEMA FGFR2b ST Basket Trial

Phase: I/II

Gall Bladder Cancer

Ph2/3 CTX-009 + Paclitaxel vs. Paclitaxel in mBiliary Tract

A Phase 2/3 Randomized Controlled Study of CTX-009 in Combination with Paclitaxel versus Paclitaxel Alone in Adult Patients with Unresectable Advanced Metastatic or Recurrent Biliary Tract Cancers who have received One Prior Systemic Chemotherapy Regimen (CTX-009-002) Read Moreabout Ph2/3 CTX-009 + Paclitaxel vs. Paclitaxel in mBiliary Tract

Phase: II/III

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Gastric Cancer

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Gynecology- Endometrial

A Phase 2 Multi-center Open-label Trial of nab-Sirolimus in Combination with Letrozole in Advanced or Recurrent Endometrioid Endometrial Cancer

Phase: II

Head and Neck Cancer

Ph1b/2 BEMA FGFR2b ST Basket Trial

A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104) Read Moreabout Ph1b/2 BEMA FGFR2b ST Basket Trial

Phase: I/II

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in Head and Neck

Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01) Read Moreabout Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in Head and Neck

Phase: I/II

Hematologic

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

PATHFINDER 2 Early Detection Test

The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012) Read Moreabout PATHFINDER 2 Early Detection Test

Phase: IV

Leukemia

STAR: Zanu in Acala intolerant B-Cell

A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215) Read Moreabout STAR: Zanu in Acala intolerant B-Cell

Phase: II

Ph2 Asciminib (ABL001) CP-CML

A Phase II multi-center open-label single-arm dose escalation study of Asciminib monotherapy in 2nd and 1st Line Chronic Phase - Chronic Myelogenous Leukemia (ASC2ESCALATE)(CABL001AUS08) Read Moreabout Ph2 Asciminib (ABL001) CP-CML

Phase: II

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Liver Cancer

Ph1b-XL092 Immun Onco mST

A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002) Read Moreabout Ph1b-XL092 Immun Onco mST

Phase: I

Ph1b/2 BEMA FGFR2b ST Basket Trial

A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104) Read Moreabout Ph1b/2 BEMA FGFR2b ST Basket Trial

Phase: I/II

Ph2 Livmoniplimab Hepatocellular Carcinoma (HCC)

A Phase 2 Randomized Open-Label Study to Evaluate the Optimized Dose Safety and Efficacy of Livmoniplimab in Combination with Budigalimab for locally advanced or Metastatic Hepatocellular Carcinoma (HCC) patients who have progressed after an approved immune checkpoint inhibitor containing regimen in 1L HCC (M24-147) Read Moreabout Ph2 Livmoniplimab Hepatocellular Carcinoma (HCC)

Phase: II

Ph3 Atezolizumab and Bevacizumab in Pts w/ mHepatocellular Carcinoma

A PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY EVALUATING ATEZOLIZUMAB AND BEVACIZUMAB WITH OR WITHOUT TIRAGOLUMAB IN PATIENTS WITH UNTREATED LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA (CO44668) Read Moreabout Ph3 Atezolizumab and Bevacizumab in Pts w/ mHepatocellular Carcinoma

Phase: III

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Lung Cancer

Ph1/2 of Quarat Ozeplasmid and Atezolizumab with SCLC (ES-SCLC) (Acclaim-3)

A Phase 1/2 Clinical Trial of Quaratusugene Ozeplasmid and Atezolizumab Maintenance Therapy in Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) (ONC-005) Read Moreabout Ph1/2 of Quarat Ozeplasmid and Atezolizumab with SCLC (ES-SCLC) (Acclaim-3)

Phase: I/II

Ph1b/2 BEMA FGFR2b ST Basket Trial

A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104) Read Moreabout Ph1b/2 BEMA FGFR2b ST Basket Trial

Phase: I/II

Ph2 MRTX849 Pembro NSCLC KRAS

A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007) Read Moreabout Ph2 MRTX849 Pembro NSCLC KRAS

Phase: II/III

Ph1 SPYK04 Solid Tumors

A PHASE I OPEN-LABEL MULTICENTER DOSE ESCALATION AND COHORT EXPANSION STUDY OF SPYK04 AS MONOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS (SPK101JG) Read Moreabout Ph1 SPYK04 Solid Tumors

Phase: I

Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3)

A Randomized Controlled Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Squamous NSCLC (HARMONi-3)(SMT112-3003) Read Moreabout Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3)

Phase: III

Ph3 DXd +Pembro NSCLC (Tropion-LUNG08) PD-L1 >50%

A Randomized Open-label Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naive Subjects with Advanced or Metastatic PD-L1 High (TPS>=50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (Tropion-Lung08)(Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects with Advanced or Metastatic NSCLC Without Actionable Genomic Alterations)(DS1062-A-U304) Read Moreabout Ph3 DXd +Pembro NSCLC (Tropion-LUNG08) PD-L1 >50%

Phase: III

Ph3 Dato-Dxd Pembro PD-L1 <50% NSCLC (TL07)

A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab with or Without Platinum Chemotherapy in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07) (DS1062-A-U303) Read Moreabout Ph3 Dato-Dxd Pembro PD-L1 <50% NSCLC (TL07)

Phase: III

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Biomarker status NSCLC

MASTER SCREENING STUDY TO DETERMINE BIOMARKER STATUS AND POTENTIAL TRIAL ELIGIBILITY FOR PATIENTS WITH MALIGNANT TUMORS (BX43361) Read Moreabout Biomarker status NSCLC

Ph1 of Gmma Delta T-Cell Infusions in combo w/subjects mNSCLC

Phase 1 Trial Evaluating the Safety and Tolerability of Gamma Delta TCell Infusions in Combination with Low Dose Radiotherapy in Subjectswith Stage 4 Metastatic Non-Small Cell Lung Cancer.(DELTACEL-01) Read Moreabout Ph1 of Gmma Delta T-Cell Infusions in combo w/subjects mNSCLC

Phase: I

ONC-392 vs. Docetaxel in PD-1 Resistant Non-small Cell Lung Cancer

Phase 3 Two-stage Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003) Read Moreabout ONC-392 vs. Docetaxel in PD-1 Resistant Non-small Cell Lung Cancer

Phase: III

Lymphomas

Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph

A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302) Read Moreabout Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph

Phase: I

STAR: Zanu in Acala intolerant B-Cell

A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215) Read Moreabout STAR: Zanu in Acala intolerant B-Cell

Phase: II

Ph2 Epco r/r B-Cell Lymph out pt

A Phase 2 Open-Label Trial to Evaluate Safety of Epcoritamab monotherapy in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma and Classic Follicular Lymphoma (Previously Grade 1-3a) when Administered in the Outpatient Setting (M23-362) Read Moreabout Ph2 Epco r/r B-Cell Lymph out pt

Phase: II

A Phase 2/3, Multicenter, Randomized, Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R_GDP) With or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Phase: II/III

Ph2 Sub Mosunetuzumab B-cell malig

AN OPEN-LABEL MULTICENTER PHASE II TRIAL EVALUATING THE SAFETY EFFICACY AND PHARMACOKINETICS OF SUBCUTANEOUS MOSUNETUZUMAB MONOTHERAPY IN PATIENTS WITH SELECT B-CELL MALIGNANCIES (ML43389) Read Moreabout Ph2 Sub Mosunetuzumab B-cell malig

Phase: II

LTFU PROTOCOL FOR SUBJECTS TREATED WITH GENE-MODIFIED T CELLS.

GC-LTFU-001: LONG-TERM FOLLOW-UP PROTOCOL FOR SUBJECTS TREATED WITH GENE-MODIFIED T CELLS. Read Moreabout LTFU PROTOCOL FOR SUBJECTS TREATED WITH GENE-MODIFIED T CELLS.

Phase: II/III

Melanoma

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Myelodysplastic Syndrome

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Myelofibrosis

A PHASE 1/2 STUDY TO EVALUATE SAFETY AND EFFICACY OF SELINEXOR, A SELECTIVE INHIBITOR OF NUCLEAR EXPORT, IN COMBINATION WITH RUXOLITINIB IN TREATMENT NAÏVE PATIENTS WITH MYELOFIBROSIS

Phase: I/II

An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Patients With Myelofibrosis

Phase: I

Myelomas

Ph2 Dara Lena Dexa (DRd) MM I

A phase II trial of daratumumab lenalidomide and dexamethasone (DRd) in combination with selinexor for patients with newly diagnosed multiple myeloma (USOR 20285) Read Moreabout Ph2 Dara Lena Dexa (DRd) MM I

Phase: II

SCRI: MM165: Ph2 TECVAYLI in multiple myeloma patients ( IIT MM165)

A Study of Outpatient Administration of Teclistamab a BCMA-targeting Bispecific Antibody in Multiple Myeloma Patients (64007957MMY2010) Read Moreabout SCRI: MM165: Ph2 TECVAYLI in multiple myeloma patients ( IIT MM165)

Phase: II

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Ovarian Cancer

Ph1b/2 BEMA FGFR2b ST Basket Trial

A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104) Read Moreabout Ph1b/2 BEMA FGFR2b ST Basket Trial

Phase: I/II

Ph1 SPYK04 Solid Tumors

A PHASE I OPEN-LABEL MULTICENTER DOSE ESCALATION AND COHORT EXPANSION STUDY OF SPYK04 AS MONOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS (SPK101JG) Read Moreabout Ph1 SPYK04 Solid Tumors

Phase: I

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Pancreatic Cancer

Ph1/2 Azeliragon refrac to 1st Line Pancreatic

A Phase I/II Open Label Study to Assess Safety and Preliminary Evidence of a Therapeutic Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer (CAN-201) Read Moreabout Ph1/2 Azeliragon refrac to 1st Line Pancreatic

Phase: I/II

SCRI:GI 348 :Ph1b/2 NabPac+ Gem +/- Botens Pancreatic 5FU +leuc Irin Oxal (FOLFIRINOX)

A PHASE II RANDOMIZED OPEN-LABEL TRIAL OF NAB-PACLITAXEL +GEMCITABINE WITH OR WITHOUT BOTENSILIMAB (Agen1181) IN PATIENTS WITH METASTATIC PANCREATIC CANCER WHO HAVE PROGRESSED ON PRIOR 5FU + LEUCOVORIN+ IRINOTECAN +OXALIPLATIN (FOLFIRINOX) Read Moreabout SCRI:GI 348 :Ph1b/2 NabPac+ Gem +/- Botens Pancreatic 5FU +leuc Irin Oxal (FOLFIRINOX)

Phase: I/II

Ph2 Study of TTX-030 treatment of patients not previously treated for met Pancreatic Adenocarcinoma

An open-label multicenter 3-arm randomized Phase 2 study to assess the efficacy and safety of TTX-030 and chemotherapy with or without budigalimab compared to chemotherapy alone for the treatment of patients not previously treated for metastatic pancreatic adenocarcinoma (TTX-030-003) Read Moreabout Ph2 Study of TTX-030 treatment of patients not previously treated for met Pancreatic Adenocarcinoma

Phase: II

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Peritoneal Cancer

Ph1b/2 BEMA FGFR2b ST Basket Trial

A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104) Read Moreabout Ph1b/2 BEMA FGFR2b ST Basket Trial

Phase: I/II

Prostate Cancer

Ph1b-XL092 Immun Onco mST

A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002) Read Moreabout Ph1b-XL092 Immun Onco mST

Phase: I

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Rectal Cancer

Ph1b-XL092 Immun Onco mST

A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002) Read Moreabout Ph1b-XL092 Immun Onco mST

Phase: I

Ph2 RO7198457 CRC ctDNA+ Post Resection

A multi-site open-label Phase II randomized controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection (BNT122-01) Read Moreabout Ph2 RO7198457 CRC ctDNA+ Post Resection

Phase: II/III

Ph2 Epidemi Colon Cancer

Epidemiological study to determine the prevalence of ctDNA positivity in participants with Stage II (high risk) or Stage III CRC after surgery with curative (R0) intent and subsequent adjuvant chemotherapy with monitoring of ctDNA during clinical follow-up (BNT000-001) Read Moreabout Ph2 Epidemi Colon Cancer

Phase: II/III

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Renal Cancer

Ph1b-XL092 Immun Onco mST

A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002) Read Moreabout Ph1b-XL092 Immun Onco mST

Phase: I

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Skin Cancer

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Solid Tumors

STAR Ph1/2 MRTX849 Solids KRAS G12C

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001) Read Moreabout STAR Ph1/2 MRTX849 Solids KRAS G12C

Phase: I/II

Ph1b/2 BEMA FGFR2b ST Basket Trial

A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104) Read Moreabout Ph1b/2 BEMA FGFR2b ST Basket Trial

Phase: I/II

Ph1 SPYK04 Solid Tumors

A PHASE I OPEN-LABEL MULTICENTER DOSE ESCALATION AND COHORT EXPANSION STUDY OF SPYK04 AS MONOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS (SPK101JG) Read Moreabout Ph1 SPYK04 Solid Tumors

Phase: I

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

PATHFINDER 2 Early Detection Test

The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012) Read Moreabout PATHFINDER 2 Early Detection Test

Phase: IV

Ph2 Tumor-Agnostic Precision TAPISTRY

TUMOR-AGNOSTIC PRECISION IMMUNO-ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU (TAPISTRY) PHASE II PLATFORM TRIAL (BO41932) Read Moreabout Ph2 Tumor-Agnostic Precision TAPISTRY

Phase: II

Thyroid Cancer

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Waldenström macroglobulinemia

STAR: Zanu in Acala intolerant B-Cell

A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215) Read Moreabout STAR: Zanu in Acala intolerant B-Cell

Phase: II